Healthcare technology company using AI and genomics for precision medicine and cancer treatment.
Tempus is a healthcare technology company that leverages artificial intelligence and genomic sequencing to advance precision medicine, particularly in oncology. Founded in 2015 by Eric Lefkofsky, the company builds a platform that analyzes clinical and molecular data to help physicians make more informed treatment decisions. Tempus operates one of the largest genomic databases in the world and provides diagnostic testing, data analytics, and AI-powered insights to healthcare providers. The company went public in 2024 and continues to expand its precision medicine capabilities.
Tempus has received investment from 6 venture capital firms.
Healthcare technology company using AI and genomics for precision medicine and cancer treatment.
Tempus has received investment from Frist Cressey Ventures, Hyde Park Angels, NextGen Venture Partners, Revolution Ventures, TechNexus Venture Collaborative and 1 other investors. These venture capital firms and investors provide both capital and strategic support.
Tempus has raised $1.4B in total funding, with their most recent round being a IPO. The company operates in the Digital Health sector.
Tempus was founded in 2015 and is headquartered in Chicago, IL.
Tempus operates in the Digital Health sector. Healthcare technology company using AI and genomics for precision medicine and cancer treatment.
